Scholarlink

<p>This study evaluated the efficacy and safety of doxycycline in treating Severe <i>Mycoplasma pneumoniae</i> Pneumonia (SMPP) in children under eight years old through clinical analysis and meta-analysis. A total of 92 pediatric SMPP cases were divided into a doxycycline treatment group (44 cases) and a macrolides control group (48 cases). Compared to the control group, the doxycycline group exhibited significantly shorter cough relief time (5.4 ± 1.2 vs. 7.2 ± 1.6&#xa0;days, <i>p</i> &lt; 0.05) and pulmonary rale resolution time (6.2 ± 1.3 vs. 8.0 ± 1.7&#xa0;days, <i>p</i> &lt; 0.05). The overall treatment efficacy rate was higher in the doxycycline group (88.6% vs. 75.0%, <i>p</i> &lt; 0.05). No significant differences were found in fever resolution time or hospitalization duration (<i>p</i> &gt; 0.05). Safety analysis revealed comparable adverse event rates between groups (18.2% vs. 16.7%, <i>p</i> &gt; 0.05), primarily mild rash and gastrointestinal discomfort, with no tooth discoloration observed. The meta-analysis confirmed the advantages of doxycycline, demonstrating superior treatment efficacy (RR: 0.68, 95% CI: 0.58–0.79), shorter fever resolution (MD: − 1.5&#xa0;days, 95% CI: − 2.3 to − 0.7), and faster cough and pulmonary rale resolution. Adverse events were similar across groups. These findings highlight doxycycline’s clinical efficacy and safety in SMPP treatment, providing strong evidence for its application in pediatric practice.</p> Graphical Abstract <p></p> <p>Summary of the efficacy and safety of doxycycline in the treatment of SMPP.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of doxycycline for severe Mycoplasma pneumoniae pneumonia in pediatric patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月22日

查看全文
  • Qian Zhao,
  • Xu Sang,
  • Ding Gao,
  • Zhen Zhang,
  • Aili Xuan,
  • Wansheng Peng

摘要

This study evaluated the efficacy and safety of doxycycline in treating Severe Mycoplasma pneumoniae Pneumonia (SMPP) in children under eight years old through clinical analysis and meta-analysis. A total of 92 pediatric SMPP cases were divided into a doxycycline treatment group (44 cases) and a macrolides control group (48 cases). Compared to the control group, the doxycycline group exhibited significantly shorter cough relief time (5.4 ± 1.2 vs. 7.2 ± 1.6 days, p < 0.05) and pulmonary rale resolution time (6.2 ± 1.3 vs. 8.0 ± 1.7 days, p < 0.05). The overall treatment efficacy rate was higher in the doxycycline group (88.6% vs. 75.0%, p < 0.05). No significant differences were found in fever resolution time or hospitalization duration (p > 0.05). Safety analysis revealed comparable adverse event rates between groups (18.2% vs. 16.7%, p > 0.05), primarily mild rash and gastrointestinal discomfort, with no tooth discoloration observed. The meta-analysis confirmed the advantages of doxycycline, demonstrating superior treatment efficacy (RR: 0.68, 95% CI: 0.58–0.79), shorter fever resolution (MD: − 1.5 days, 95% CI: − 2.3 to − 0.7), and faster cough and pulmonary rale resolution. Adverse events were similar across groups. These findings highlight doxycycline’s clinical efficacy and safety in SMPP treatment, providing strong evidence for its application in pediatric practice.

Graphical Abstract

Summary of the efficacy and safety of doxycycline in the treatment of SMPP.